Investors were disappointed with Abbott Laboratories' ( NYSE:ABT ) earnings, despite the strong profit numbers.

With this in mind, three Motley Fool contributors have identified dividend stocks that they think retirees should absolutely ...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, ...

An Abbott official said today that the company launched its latest-generation MitraClip and TriClip G5 systems.

Abbott’s Q2 showed resilience amid macro risks, with its dividend strength and fair valuation reinforcing long-term appeal.

The US Food and Drug Administration (FDA) has approved Anbogen Therapeutics’ investigational new drug (IND) application for ...

A former high-ranking official in the governor's administration is one of leaders poised to run "Y'all Street." ...

THW trades at a favorable discount to NAV and it's a potential accumulation opportunity, though risks remain if rates stay ...

U.S. stocks rallied and won back most of their sharp loss from last week. The S&P 500 jumped 1.5% Monday to follow up its ...

Wall Street is rising, led by a rally for Apple. The S&P 500 climbed 0.7% Wednesday. The Dow Jones Industrial Average added ...

U.S. stocks rallied to recover most of their sharp loss from Friday's wipeout. The S&P 500 rose 1.5% Monday, following its ...

U.S. stocks are rallying to recover more than two thirds of their sharp loss from Friday's wipeout. The S&P 500 rose 1.2% ...